Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateWill Eli Lilly (LLY) Q2 Mounjaro sales be above __?
Will Eli Lilly (LLY) Q2 Mounjaro sales be above __?
BAGO
Aug 5, 2026
$7.5B
96%
$8.25B
91%
$9B
86%
$9.75B
39%
$10.5B
11%
$483 Vol.
$7.5B
$40 Vol.
96%
$8.25B
$120 Vol.
91%
$9B
$81 Vol.
86%
$9.75B
$141 Vol.
39%
$10.5B
$101 Vol.
11%
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Binuksan ang Market: Jul 27, 2026, 1:43 PM ET
Volume
$483Petsa ng Pagtatapos
Aug 5, 2026Binuksan ang Market
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
This market will resolve to "Yes" if Eli Lilly's Mounjaro total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$483Petsa ng Pagtatapos
Aug 5, 2026Binuksan ang Market
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...Eli Lilly’s Mounjaro (tirzepatide) continues to drive outsized revenue growth amid robust demand for GLP-1 therapies. Worldwide sales reached $8.7 billion in Q1 2026, up 125% year-over-year, with U.S. volume expanding sharply even as realized prices declined in the low- to mid-teens percent range due to rebates and formulary shifts. International expansion, including China NRDL inclusion, added meaningful contribution. Analysts project Q2 2026 company revenue near $20.5 billion, implying sustained momentum for the tirzepatide franchise ahead of the late-July earnings release. Key variables include prescription trends, supply availability, competitive pressure from Novo Nordisk, and any one-time pricing adjustments that could influence the final reported figure relative to market-implied thresholds.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong